After years of maintaining the status quo in ovarian cancer treatment, a number of recent advances have challenged the paradigm based on intravenous (IV) taxane and platinum as the therapy of choice for advanced ovarian cancer. These new data are summarized concisely by Liu and Matulonis in this issue. More »
Epithelial ovarian cancer is the leading cause of death from gynecologic malignancy in the United States, with approximately 15,000 deaths per year. Platinum/taxane doublets have long been considered the standard treatment regimen for advanced-stage disease; however, recent studies have sought to improve on the outcome from this therapy. Intraperitoneal (IP) chemotherapy has been shown to yield superior progression-free survival (PFS) and overall survival (OS); however, logistical problems and... More »
As outlined in the excellent, comprehensive review by Drs. Liu and Matulonis, ovarian cancer is the most lethal gynecologic malignancy in the United States, with approximately 16,000 deaths and 22,000 new cases yearly.[1] The vast majority of patients present with intra-abdominal spread of disease at the time of diagnosis, resulting in low overall cure rates. As outlined, patients are primarily managed with primary surgical resection and subsequent platinum-based chemotherapy. More »
Postmenopausal women at average risk of ovarian cancer may benefit from ROCA (Risk of Ovarian Cancer Algorithm), a new ovarian cancer screening strategy that combines information about trends in CA-125 blood test results and age, followed by transvaginal ultrasound (TVU) as needed and referral to a gynecologic oncologist. Results of a prospective multicenter trial of ROCA were reported at the 44th annual meeting of ASCO (abstract 5003). Results of ROCA testing were used to categorize women as... More »
carcinoma. METHODS: We assayed surgically obtained ovariancancer and mesothelial cells and both native and engineered ovariancancer cell ...ovariancancer tissue specimens. In serous ovariancancer patients with CD157 H scores of 60 or greater had statistically significantly ...
IL-6 is elevated in the serum and ascites of ovariancancer patients and increased IL-6 concentration correlates with poor prognosis and chemoresistance. ... phenotype and the underlining mechanisms of drug resistance in ovariancancer cells remain unclear. Here we demonstrate that both exogenous ...
cancer. METHODS: Expression of EVI1 mRNA and protein isoforms was evaluated in ovariancancers normal ovaries benign ovarian neoplasms ...cancers. EVI1 protein expression patterns were similar between serous ovariancancer samples fallopian tube fimbria and benign neoplasms. ...
amino acid transporter gene expression and proliferation in human ovariancancer cell lines. Expression of three cancer-associated amino acid ... The system L amino acid transporter LAT1 was up-regulated in human ovariancancer SKOV3 IGROV1 A2780 and OVCAR3 cells compared to normal ovarian ...
one of the most important determinants of the outcome in ovariancancer patients. Surgery by a gynaecological oncologist in a specialised ... likelihood of favourable outcome for patients with advanced-stage ovariancancer. Population-based studies in Europe however show that a substantial ...
